Parazero stock rises after receiving second major defense order

Investing.com -- Kyivstar Group Ltd. (NASDAQ:KYIV) stock fell 8.7% on Friday after the company announced the pricing of a public offering of 12.5 million common shares by its principal shareholder and other selling shareholders.

The shares were priced at $10.50 each, according to the Ukrainian digital operator. Kyivstar itself is not selling any common shares in the offering, which is expected to close on February 2, 2026, subject to customary closing conditions.

The selling shareholders, including VEON Amsterdam B.V., have granted the underwriters a 30-day option to purchase up to an additional 1,875,000 common shares at the public offering price, less underwriting discounts and commissions.

Morgan Stanley, Barclays, Cantor, and Rothschild & Co are acting as joint book-running managers and representatives of the underwriters for the offering. Benchmark, a StoneX Company, and Northland Capital Markets are serving as co-managers.

Kyivstar Group operates JSC Kyivstar, which is Ukraine’s leading digital operator and the first Ukrainian company to list on a U.S. stock exchange. The company provides various connectivity and digital services, including mobile and fixed-line voice and data, ride-hailing, e-health, digital TV, and enterprise solutions such as Big Data, cloud, and cybersecurity.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) stock fell 14.9% Friday after the company announced the pricing of its previously announced underwritten public offering of 32 million shares of common stock at $1.30 per share.

The biopharmaceutical company expects to raise gross proceeds of $41.6 million from the public offering before deducting underwriting discounts and commissions and other expenses. The offering is expected to close around February 2, 2026, subject to customary closing conditions.

In addition to the public offering, Lexicon has agreed to sell shares in a concurrent private placement for expected gross proceeds of approximately $41.1 million. This private placement includes 22.4 million shares of common stock at $1.30 per share and 184,366 shares of Series B Convertible Preferred Stock at $65.00 per share to an affiliate of Invus, L.P., Lexicon’s largest stockholder.

The company also announced that the private placement purchaser has agreed to buy an additional 182,779 shares of Series B Convertible Preferred Stock at $65.00 per share, which is expected to generate approximately $11.9 million in additional gross proceeds.

Lexicon intends to use the net proceeds from both offerings to fund continued research and development of its drug candidates and for working capital and general corporate purposes.

Jefferies and Piper Sandler are serving as joint book-running managers for the public offering, with H.C. Wainwright & Co. acting as lead manager.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.